IBT 9401Alternative Names: Chondroitinase AC
Latest Information Update: 29 Mar 2006
At a glance
- Originator BioMarin Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer metastases
Most Recent Events
- 29 Mar 2006 No development reported - Preclinical for Cancer metastases in Canada (unspecified route)
- 04 Dec 2003 This compound is still in active development
- 16 Jul 2001 New profile